>

NanoSyrinx at Number 10

Our CEO Joe Healey was invited to Number 10 this week, to discuss the future of Engineering Biology in the UK as part of a networking and investment breakfast.

Synthetic biology or “Engineering Biology” has been highlighted as one of the five key technology areas for the UK’s future economy. Understanding how best to incubate, invest in, promote and unlock future innovations in the sector is therefore a high priority for policy makers and those in the industry.

The UK currently ranks third globally in total private investment in engineering biology and is home to more biotech start-ups than anywhere else in Europe. The UK Government is committed to building on this success, supporting more companies to start and scale in the UK and supporting our mission to become a science and technology superpower.

Engagement with companies and academics in the space is crucial to ensuring that this happens in the most optimal way.

 

Read more news

NanoSyrinx CEO Joe Healey appointed to DSIT’s Engineering Biology Steering Group

In 2023, the UK Government published the “National Vision for Engineering Biology”. The report highlighted the ambitions of the UK to be a world leader in the Engineering Biology (a.k.a. Synthetic Biology) sector, and described how £2BN would be put to work over the next decade, cementing the UK’s position at the front of the […]

Read more

NanoSyrinx at Number 10

Our CEO Joe Healey was invited to Number 10 this week, to discuss the future of Engineering Biology in the UK as part of a networking and investment breakfast. Synthetic biology or “Engineering Biology” has been highlighted as one of the five key technology areas for the UK’s future economy. Understanding how best to incubate, […]

Read more

JPM week 2024: NanoSyrinx highlighted in GEN

NanoSyrinx CEO Joe Healey, and CBO James Lapworth attended the JP Morgan Healthcare conference in San Francisco last week. Among a great week of meetings with collaborators, investors and partners, they sat down with Jonathan Grinstein PhD, a writer for GEN Edge, and spoke about the journey the company had been on and the outlook […]

Read more